drugset
drugset / Trial / NCT04482712

Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS

NCT04482712 ↗

Phase 1/2 Withdrawn The University of Texas Health Science Center at San Antonio The Claude D. Pepper Older Americans Independence Centers · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study assesses the clinical effectiveness of mammalian target of rapamycin (mTOR) inhibition with rapamycin in minimizing or decreasing the severity of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in participants infected with mild to moderate COVID-19 virus.

Timeline

Start
2021-04
Primary completion
2022-01
Completion
2023-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sirolimus Small molecule 1 mg —

Indications

COVID-19 acute respiratory distress syndrome